Avalyn Pharma (NASDAQ:AVLN) Reaches New 52-Week High - Time to Buy?

Key Points

• Avalyn Pharma reached a new 52-week high, trading as high as $33.49 and closing near $32.93, with a market capitalization of approximately $1.47 billion.
• Analyst sentiment is broadly positive: the stock has an average “Buy” rating and a consensus price target of $59, with recent targets ranging from $51 to $53.
• The clinical-stage biopharmaceutical company reported a quarterly EPS loss of $21.83, missing expectations by $5.45, while developing inhaled therapies for serious rare respiratory diseases, including pulmonary fibrosis.

Avalyn Pharma Inc. (NASDAQ:AVLN - Get Free Report) hit a new 52-week high during mid-day trading on Friday . The stock traded as high as $33.49 and last traded at $32.93, with a volume of 11152 shares. The stock had previously closed at $32.70.

Analyst Ratings Changes

A number of equities analysts recently issued reports on AVLN shares. Evercore assumed coverage on Avalyn Pharma in a report on Tuesday, May 26th. They issued an "outperform" rating and a $51.00 price objective for the company. Jefferies Financial Group initiated coverage on Avalyn Pharma in a research note on Monday, May 25th. They set a "buy" rating and a $52.00 target price on the stock. Zacks Research upgraded Avalyn Pharma to a "hold" rating in a research report on Wednesday, May 27th. Morgan Stanley initiated coverage on Avalyn Pharma in a research note on Tuesday, May 26th. They issued an "overweight" rating and a $53.00 price target for the company. Finally, Wall Street Zen raised Avalyn Pharma to a "hold" rating in a report on Saturday, May 9th. Two investment analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating and one has assigned a Hold rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus price target of $59.00.

Avalyn Pharma Price Performance

The company has a 50 day moving average of $29.04. The company has a market capitalization of $1.47 billion and a P/E ratio of -1.52.

Avalyn Pharma (NASDAQ:AVLN - Get Free Report) last posted its quarterly earnings data on Wednesday, June 3rd. The company reported ($21.83) earnings per share (EPS) for the quarter, missing the consensus estimate of ($16.38) by ($5.45). On average, research analysts expect that Avalyn Pharma Inc. will post -3.45 earnings per share for the current year.

Hedge Funds Weigh In On Avalyn Pharma

An institutional investor recently bought a new stake in Avalyn Pharma stock. Bank of New York Mellon Corp bought a new stake in shares of Avalyn Pharma Inc. (NASDAQ:AVLN - Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 40,140 shares of the company's stock, valued at approximately $1,321,000. Bank of New York Mellon Corp owned approximately 0.09% of Avalyn Pharma as of its most recent SEC filing.

Avalyn Pharma Company Profile

We are a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases with significant unmet needs. Our approach is designed to address the limitations of current oral therapies by delivering optimized inhaled formulations of approved oral medicines directly to the lungs to enhance efficacy and minimize systemic exposure that contributes to side effects and treatment discontinuation. Our current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source